Posts

Posted on

Independent Bank Corporation Announces Date for Its First Quarter 2025 Earnings Release

GRAND RAPIDS, Mich., March 28, 2025 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP), the holding company of Independent Bank, a Michigan-based community bank, announced that it expects to issue its 2025 first quarter results on Thursday, April 24, 2025, at approximately 8:00 am ET. The release will be available on the Internet at IndependentBank.com within the “News” section of the “Investor Relations” area of the Company’s website.

Brad Kessel, President and CEO, Gavin Mohr, CFO and Joel Rahn, EVP Commercial Banking will review the quarterly results in a conference call for investors and analysts beginning at 11:00 am ET on Thursday, April 24, 2025.

To participate in the live conference call, please dial 1-833-470-1428 (Access Code # 706949). Also, the conference call will be accessible through an audio webcast with user-controlled slides via the following event site/URL: https://events.q4inc.com/attendee/106805636.

A playback of the call can be accessed by dialing 1-866-813-9403 (Access Code # 746507). The replay will be available through May 1, 2025.


About Independent Bank Corporation

Independent Bank Corporation (NASDAQ: IBCP) is a Michigan-based bank holding company with total assets of approximately $5.3 billion. Founded as First National Bank of Ionia in 1864, Independent Bank Corporation operates a branch network across Michigan’s Lower Peninsula through one state-chartered bank subsidiary. This subsidiary (Independent Bank) provides a full range of financial services, including commercial banking, mortgage lending, investments, insurance and title services. Independent Bank Corporation is committed to providing exceptional personal service and value to its customers, stockholders and the communities it serves.

For more information, please visit our website at: IndependentBank.com.

Contact: William B. Kessel, President and CEO, 616.447.3933
  Gavin A. Mohr, Chief Financial Officer, 616.447.3929



Posted on

TGT Deadline: TGT Investors Have Opportunity to Lead Target Corporation Securities Fraud Lawsuit

PR Newswire


NEW YORK
, March 28, 2025 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Target Corporation (NYSE: TGT) between August 26, 2022 and November 19, 2024, both dates inclusive (the “Class Period”), of the important April 1, 2025 lead plaintiff deadline.

So what: If you purchased Target common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Target class action, go to https://rosenlegal.com/submit-form/?case_id=6812 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 1, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, Target misled investors by making false and misleading statements about Target’s Environmental, Social and Governance (“ESG”) and Diversity, Equity, and Inclusion (“DEI”) mandates that led to widespread customer boycotts following Target’s 2023 LGBT-Pride Campaign (the “Campaign”). The negative effects of the Campaign on Target’s business, including a subsequent campaign in 2024 (the “2024 Campaign”), led to a massive decline in Target’s stock price.

Specifically, the Campaign offended certain Target customers, provoking consumer backlash and boycotts that caused Target’s sales to fall for the first time in six years. Unbeknownst to investors, and contrary to Target’s public statements, its Chief Executive Officer (“CEO”) and Board of directors did not oversee or disclose the known risks of Target’s 2023 or 2024 Campaigns. This deceit, through misleading statements in Target’s public filings, caused Target investors to purchase Target stock at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Target class action, go to https://rosenlegal.com/submit-form/?case_id=6812 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tgt-deadline-tgt-investors-have-opportunity-to-lead-target-corporation-securities-fraud-lawsuit-302414438.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

Baidu’s Apollo Go Partners with Autogo in Plan to Build Abu Dhabi’s Largest Robotaxi Fleet

PR Newswire

  • During the initial period, Apollo Go and Autogo will collaborate to deploy dozens of autonomous vehicles in Abu Dhabi, with phased expansion planned ahead of full commercial operations by 2026.
  • This marks Apollo Go’s further expansion into the UAE, applying its proven autonomous driving technology and operational experience from China.
  • Apollo Go and Autogo will collaborate to scale commercial operations and expect to build Abu Dhabi’s largest driverless fleet.


BEIJING
, March 28, 2025 /PRNewswire/ — Baidu (NASDAQ: BIDU and HKEX: 9888) announced today (March 29, 2025, Beijing Time) that its autonomous ride-hailing service, Apollo Go, has entered into a strategic partnership with Autogo, a UAE-based autonomous mobility company and subsidiary brand of Kintsugi Holding, with the goal of deploying the largest fully driverless fleet in Abu Dhabi. Through this strategic partnership, Apollo Go and Autogo aim to bring next-generation mobility to the streets of the UAE capital.

Initial trials of dozens of Apollo Go autonomous vehicles will be deployed in select areas of Abu Dhabi, with phased expansion planned ahead of full commercial operations by 2026. The trials in Abu Dhabi will be conducted in close coordination with the city’s Integrated Transport Centre (ITC), ensuring that the service aligns with local transport strategies, regulatory standards, and infrastructure planning as part of the emirate’s smart mobility goals.

By combining Apollo Go’s cutting-edge technology in autonomous driving and extensive experience in large-scale fleet operations, this partnership will enable Abu Dhabi and Autogo to rapidly build a smart mobility service ecosystem. Apollo Go’s proven solutions will integrate seamlessly with Autogo’s local expertise and market insight, offering residents a more convenient and sustainable transportation experience.

As Baidu’s robotaxi arm, Apollo Go stands as China’s largest of its kind. Since February 2025, Apollo Go has commenced 100% fully driverless operations across over 10 cities in China and continues to expand. In November 2024, Apollo Go was granted the first autonomous vehicle pilot license in Hong Kong, its first entry into a right-hand drive, left-hand traffic market.

Backed by 150 million kilometers of safe autonomous driving track record and over 10 million cumulative rides, Apollo Go brings proven technology and operational experience to the UAE, and is poised to enhance the city’s transportation efficiency and smart mobility solutions. As an all-electric, on-demand service, Apollo Go also promotes a more sustainable approach to urban transportation — helping reduce emissions, ease congestion, and reshape the city landscape.

Looking ahead, Apollo Go and Autogo will work together to scale commercial operations of robotaxi services to serve more users and contribute to Abu Dhabi’s smart city vision.

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on the NASDAQ under “BIDU” and HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.

Media Contact:
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/baidus-apollo-go-partners-with-autogo-in-plan-to-build-abu-dhabis-largest-robotaxi-fleet-302414551.html

SOURCE Baidu, Inc.

Posted on

Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as well as the first presentation of the MTA3D™ Adductoplasty® clinical study, at the 2025 American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting in Phoenix, Arizona.

“We are excited to feature our growing body of clinical data to surgeons attending the 2025 ACFAS conference,” stated John T. Treace, CEO, Founder and Board Member of Treace. “This builds on our commitment to support our flagship Lapiplasty® and Adductoplasty® procedures with clinical evidence and notably marks the first meeting where all three of our prospective, multicenter studies are presented, including our ALIGN3D™, Mini3D™, and MTA3D™ studies, demonstrating positive clinical outcomes and further differentiating these procedures with surgeons and patients.”

ALIGN3D™ Lapiplasty

®

Clinical Study Presentation

ALIGN3D™ clinical study results presented by Daniel Hatch, DPM (Foot & Ankle Center of the Rockies, Greeley, CO) on Friday, March 28 as a podium presentation entitled, “Four-Year Analysis of a Five-Year Prospective Multicenter Study Assessing Radiographic Recurrence and Patient Outcomes Following Triplanar Tarsometatarsal Arthrodesis with Early Weightbearing.” The featured interim data from the prospective, five-year, multicenter ALIGN3D™ clinical study of the Lapiplasty® Procedure included interim analysis of 135 of 173 patients treated with at least four years of follow-up. The data showed:

  • Early return to protected weight bearing at an average 8.4 days;
  • Low radiographic recurrence rates of 0.8% using HVA>20° and 7.7% using HVA>15° at 48 months; and
  • Continued significant improvement in pain and patient-reported outcome scores (MOxFQ and PROMIS) at 48 months.

Mini3D™ Lapiplasty Mini-Incision™ Clinical Study Presentation

Mini3D™ clinical study results presented by Jody McAleer, DPM (Jefferson City Medical Group, Jefferson City, MO) on Friday, March 28 as a podium presentation entitled, “Prospective Multicenter Study Assessing Radiographic and Patient Outcomes Following an Instrumented Mini-Open Triplanar Tarsometatarsal Arthrodesis with Early Weightbearing.” The featured results of this prospective, multicenter Mini3D™ clinical study of the Lapiplasty® Mini-Incision™ Procedure (median incision length: 3.5cm) included interim analysis of 75 of 105 patients treated with at least one year follow-up. The data showed:

  • Early return to protected weightbearing at an average 7.9 days;
  • Low radiographic recurrence rates of 0.0% using HVA>20° and 5.5% using HVA>15° at 12 months; and
  • Significant improvements in pain and patient-reported scores (MOxFQ and PROMIS) at 12 months.  

MTA3D™ Adductoplasty

®

Clinical Study Presentation

MTA3D™ clinical study results presented by Paul Dayton, DPM (Foot and Ankle Center of Iowa, Ankeny, IA) on Friday, March 28 as a poster presentation, entitled “Interim 1-Year Analysis of a Prospective Multicenter Study Assessing Radiographic and Patient-Reported Outcomes Following Combined Metatarsus Adductus and Hallux Valgus Correction through 3rd, 2nd, and 1st Tarsometatarsal Arthrodesis with Early Weightbearing.” The featured interim data from the prospective, five-year, multicenter MTA3D™ clinical study of the patients undergoing both the Adductoplasty® and Lapiplasty® procedures included interim analysis of 18 of 38 patients treated with at least one year follow-up. The data showed:

  • Early return to protected weightbearing at an average 7.5 days;
  • Clinically significant improvement relative to baseline in radiographic measures of both midfoot (metatarsus adductus) and 3D bunion deformity correction at 12 months; and
  • Clinically significant reduction in pain and patient-reported scores (MOxFQ and PROMIS) at 12 months.

Additionally, results from a retrospective study on the Adductoplasty® Procedure were presented by Jody McAleer, DPM (Jefferson City Medical Group, Jefferson City, MO) on Friday, March 28 as a podium presentation, entitled “Instrumented Correction of Metatarsus Adductus with Hallux Valgus – A Multicenter Radiographic Assessment.” The data from this retrospective clinical study of patients undergoing both the Adductoplasty® and Lapiplasty® procedures included an analysis of 43 patients treated with a mean follow up of 17.7 months, demonstrating positive clinical results and radiographic correction of both the midfoot (metatarsus adductus) and 3D bunion deformities.

All ACFAS presentations, which include additional details such as patient demographics, inclusion/exclusion criteria, and complications reported in the studies, will be available on Treace’s website at www.lapiplasty.com/surgeons/journal-publications/ following their presentations at ACFAS.  More information on Treace’s products can be found at www.lapiplasty.com.

About the ALIGN3D™ Clinical Study
The ALIGN3D™ clinical study is a prospective, multicenter, post-market study designed to evaluate outcomes of the Lapiplasty® 3D Bunion Correction® procedure in the surgical management of symptomatic hallux valgus. The study will evaluate for consistent and reliable correction of all three dimensions of the bunion deformity with the Lapiplasty® Procedure, as well as maintenance of such correction following accelerated return to weight-bearing, initially in a walking boot. The primary effectiveness endpoint is radiographic recurrence of the hallux valgus deformity. Key secondary endpoints include change in three-dimensional radiographic alignment; clinical radiographic healing; time to start of weight-bearing in a boot and in shoes; pain; quality of life; and range of motion of the big toe joint. The study enrolled 173 patients, aged 14 to 58 years, at 7 clinical sites in the United States with 13 participating surgeons. Final patient follow-up for the primary endpoint was completed in the first half of 2023.

About the Mini3D™ Clinical Study
The Mini3D™ clinical study is a prospective, multicenter, post-market study designed to evaluate the ability of the Lapiplasty® Mini-Incision™ Procedure to consistently and reliably correct all three dimensions of the bunion deformity and maintain the correction following accelerated return to weight-bearing. The study’s primary endpoint is radiographic recurrence of the bunion deformity at 24 months follow up. Secondary endpoints include changes in three-dimensional radiographic alignment; clinical radiographic healing; time to start of weight-bearing in a boot and in shoes; pain; quality of life; range of motion of the big toe joint; scar quality; change in radiographic foot length and width as well as swelling. The study enrolled 105 patients, aged 14 to 58 years, at 9 clinical sites in the United States with 9 participating surgeons.

About the MTA3D™ Clinical Study
The MTA3D™ clinical study is a prospective, multicenter, post-market study designed to evaluate the combined Adductoplasty® and Lapiplasty® Procedures for patients in need of metatarsus adductus and hallux valgus corrective surgery. The study will evaluate for consistent, maintained radiographic correction and patient reported outcome scores following combined Adductoplasty® and Lapiplasty® procedures. The primary effectiveness endpoint is maintenance of radiographic correction of the hallux valgus and metatarsus adductus deformities. Key secondary endpoints include clinical radiographic healing, time to start weight-bearing in boot and shoes, pain, quality of life, and range of motion of the big toe joint. The study will treat up to 80 patients, aged 14 years and up, at up to 13 clinical sites in the United States. Patients will be followed for 5 years following the procedures.

Internet Posting of Information

Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion surgeons and address the four classes of bunions, Treace introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty®, Adductoplasty® and SpeedMTP™ procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

Contacts:

Treace Medical Concepts

Mark L. Hair
Chief Financial Officer
[email protected]
(904) 373-5940

Investors:
Gilmartin Group
Vivian Cervantes
[email protected]



Posted on

American Rebel Launches Nationwide Ad Campaign on March 31 with 30 Second TV Spot, Complemented by Digital Media Across Leading Websites, to Increase Exposure of the Company and its Products to Millions of Viewers


Plans to Utilize Digital Ads and Traditional Television Spots

Nashville, TN, March 28, 2025 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), creator of American Rebel Beer (americanrebelbeer.com) and a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel (americanrebel.com), has announced that it will launch an ad campaign to raise awareness and exposure for the Company. The Company anticipates running traditional television spots on CNBC and Fox Business as well as utilizing digital ads that will appear on many top-tier financial advice and investor education websites with combined monthly traffic of over 300 million followers.

“When I speak with individual investors and our customers, they often express amazement that American Rebel has accomplished what it has in such a short period of time,” said American Rebel CEO Andy Ross. “Part of our responsibility to our stockholders is to educate the broader investment community about the Company’s achievements. First of all, we’ve developed an incredible beer that is all natural with no corn syrup or rice extract. We’ve developed striking and unique packaging that is very identifiable. We’ve created strong awareness in the distributor community and reached significant distribution agreements in multiple states. We’re front and center in the entertainment district in Nashville where we’re told more beer is sold in this particular several square mile area than anywhere else in the world. This story needs to be shared far and wide.”

American Rebel has developed the TV and Digital Marketing Campaign in partnership with Martini & Partners Advertising, LLC and Martini & Partners will manage the ad placements. TV spots and digital ads are expected to begin on Monday, March 31. For more information on American Rebel, go to americanrebelbeer.com/investor-relations.

Company highlights include access to the largest co-packer in the country that has capacity to brew over 230,000,000 cases of beer annually for its customers, American Rebel Beer has an experienced team of alcohol industry professionals with over 100 years of industry experience, and American Rebel Beer benefits from support from its publicly-traded parent company, American Rebel Holdings, Inc. (NASDAQ: AREB).

American Rebel has contracted with many leading beer distributors in the country, including Clark Distributing Co and Stagnaro Distributing in Kentucky; Bonbright Distributors, Tramonte Distributing Co and Stagnaro Distributing in Ohio; Dichello Distributors in Connecticut; Gray Eagle Distributors in Missouri; Adams Beverages in North Carolina, Best Brands in Tennessee, Standard Beverage in Kansas, Mahaska Bottling Co in Iowa and Clark Beverage Group in Mississippi. These industry-leading distributors are part of the Miller/Coors Network, the Anheuser Busch Network or are a major independent distributor.

American Rebel Beer also utilizes the musical and media assets of its CEO, Andy Ross. Andy has performed for American Rebel Beer launch parties at Kid Rock’s in Nashville, The Toad in Connecticut and the MAPS Air Museum in North Canton, OH. An April launch party is scheduled for Bowling Green, KY to support American Rebel Beer’s launch in the state of Kentucky. The company also plans Rebel Light Nights throughout the country to support individual on-premise locations. One very important performance is scheduled at Fort Campbell, KY to celebrate the Army’s 250th anniversary at the home of the 101st Airborne – the Screaming Eagles.

CEO Andy Ross has appeared on Fox & Friends on Fox News, and segments on Newsmax and OAN (One America Network) to share the American Rebel story. He has also appeared on numerous local morning show network television broadcasts in San Diego, CA; Las Vegas, NV; Tampa, FL; Nashville, TN; and Kansas City, MO and multiple podcasts and radio interviews.

About American Rebel Light Beer

Produced in partnership with AlcSource, American Rebel Light Beer (americanrebelbeer.com) is a domestic premium light lager celebrated for its exceptional quality and patriotic values. It stands out as America’s Patriotic, God-Fearing, Constitution-Loving, National Anthem-Singing, Stand Your Ground Beer.

American Rebel Light is a Premium Domestic Light Lager Beer – All Natural, Crisp, Clean and Bold Taste with a Lighter Feel. With approximately 100 calories, 3.2 carbohydrates, and 4.3% alcoholic content per 12 oz serving, American Rebel Light Beer delivers a lighter option for those who love great beer but prefer a more balanced lifestyle. It’s all natural with no added supplements and importantly does not use corn, rice, or other sweeteners typically found in mass produced beers.

About American Rebel Holdings, Inc.

American Rebel Holdings, Inc. (NASDAQ: AREB) has operated primarily as a designer, manufacturer and marketer of branded safes and personal security and self-defense products and has recently transitioned into the beverage industry through the introduction of American Rebel Beer. The Company also designs and produces branded apparel and accessories. To learn more, visit americanrebelbeer.com or americanrebel.com. For investor information, visit americanrebel.com/investor-relations.

American Rebel Holdings, Inc.

[email protected]

American Rebel Beverages, LLC

Todd Porter, President
[email protected]

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. American Rebel Holdings, Inc., (NASDAQ: AREB; AREBW) (the “Company,” “American Rebel,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “forecasts” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements primarily on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include benefits of Nationwide Ad Campaign, success and availability of the promotional activities and ad campaigns, our ability to effectively execute our business plan, and the Risk Factors contained within our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2023 and Form 10-Q for the quarter ended September 30, 2024. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]



[email protected]

For Media Inquiries Contact:

[email protected]

Attachment



Posted on

GE HealthCare unveils Revolution™ Vibe CT system with Unlimited One-Beat Cardiac imaging and AI Solutions

GE HealthCare unveils Revolution™ Vibe CT system with Unlimited One-Beat Cardiac imaging and AI Solutions

  • GE HealthCare’s Revolution Vibe CTi enables more facilities to elevate patient care by offering advanced cardiac imaging technology that helps deliver fast, accurate diagnoses, improve operational efficiency, and enhance patient outcomes.
  • Cardiovascular disease (CVD) is the leading cause of death and healthcare costs worldwide,ii with research projecting it could cause over 23 million deaths by 2030.iii The average number of cardiac computed tomography (CT) procedures performed per site is expected to increase 175 percent,iv highlighting its value as a first-line imaging tool for diagnosis, treatment planning, and post-treatment follow-up.

CHICAGO–(BUSINESS WIRE)–
At the American College of Cardiology 2025 meeting, GE HealthCare (Nasdaq: GEHC) will proudly introduce Revolution™ Vibe,i a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrial fibrillation and heavily calcified coronaries. Combined with the company’s impressive ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and Effortless Workflow’s AI-powered solutions, Revolution Vibe enables fast, accurate diagnoses, a more comfortable patient experience, and more efficient workflows.v

As cardiovascular disease (CVD) continues to rise globally,vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. CCTA offers a non-invasive, cost-effective, and highly sensitive method for diagnosing coronary artery disease (CAD), making it a valuable tool for clinicians. The National Institute for Health and Care Excellence (NICE) recommends CCTA as the first-line investigation for patients with chest pain due to suspected CAD, highlighting its importance in improving diagnostic certainty. vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible.

“Expanding access to CCTA is crucial for managing the rising prevalence of CVD, ensuring timely and accurate diagnoses for a larger patient population,” shares Jean-Luc Procaccini, President and CEO, Molecular Imaging and Computed Tomography, GE HealthCare. “Our introduction of Revolution Vibe underscores our commitment to this mission. The system is designed to encourage the broader adoption of and access to cardiac imaging, combining advanced technology with AI-powered solutions to deliver fast, accurate diagnoses and a more comfortable patient experience. It is designed to empower healthcare providers to offer the highest quality care, even in the most challenging cases.”

For CCTA to be truly effective, the CT system must be designed to address the most difficult cardiac exams, including irregularities in heart rhythms, patients with limited cooperation, and those with calcification, stents or bypasses. These complications challenge cardiologists and radiologists alike, often leading to repeat scans, inaccurate diagnoses, heightened patient risk and dissatisfaction, and increased costs.viii, ix, x, xi, xii, xiii, xiv, xv

GE HealthCare designed Revolution Vibe to address these challenges. The ‘all in one’ system provides advanced cardiac CT solutions to help make CCTA more accessible to more facilities and patients, while also enabling greater diagnostic confidence, patient comfort, and workflow efficiency.

“Revolution Vibe has significantly enhanced our cardiac imaging capabilities, doubling our CCTA capacity while reducing scan times and improving image quality,” shares Dr. Christopher Ahlers, Radiologist and Managing Partner at Radiomed. “The advanced technology streamlines workflows, reduces reliance on invasive diagnostics, and ensures high-quality care for all patients, including those with challenging conditions. By adopting Revolution Vibe, we have improved operational efficiency, increased diagnostic confidence, and elevated patient satisfaction, positioning us at the forefront of cardiac care.”

Revolution Vibe enhances cardiac capabilities, enabling Unlimited One-Beat Cardiacimaging. This advanced technology offers clear, full-heart images at low dose, improving access for patients with complex conditions like atrial fibrillation, breath-holding difficulties, heavily calcified coronaries, in-stent restenosis, and cases without an ECG trace. TrueFidelity DL images for cardiac and SnapShot Freeze 2 offer Revolution Vibe users impressive image quality with motion free images. The system also offers ECG-less Cardiac to help improve patient access and simplify preparation for exams without an ECG connection, making it ideal for situations where speed is a priority or when the ECG signal is unavailable.

Effortless Cardiac Workflow also optimizes the system for cardiac scans, leveraging AI to automatically select protocols and position the patient – optimizing scanning time and making it easy to use for every user, even junior or inexperienced technologists. In a clinical evaluation, the one-step decision tree workflow helped reduce exam time by 50 percent, freeing up four minutes of radiologists’ time per study.xvi It also helped reduce the patient preparation process by up to five minutes per scan.xvi Much of this time is saved due to reduced positioning time, minimized usage of beta blockers, and eliminating the need for an ECG connection when the cardiac exam needs to be prioritized for patient access and speed.

Finally, Revolution Vibe is designed to help healthcare facilities expand their service lines and manage lifecycle costs effectively, driving topline growth. With the growing need for cardiac CT, the system’s versatility and ability to handle increased cardiac exams and general imaging needs make it accessible to more facilities.

Beyond initial costs, Revolution Vibe offers energy-efficient design, extensive training, fleet management, and Smart Subscription, ensuring facilities stay updated with the latest technology. This innovative technology maximizes operational efficiency, enhances staff expertise, and delivers better patient outcomes, making it a wise long-term investment.

For more information on Revolution Vibe, please visit gehealthcare.com. Those attending the American College of Cardiology (ACC) 2025 meeting in Chicago are also invited to experience the system’s formal unveiling in GE HealthCare’s booth (#9013) on Saturday, March 29 at 10:30 a.m.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

i Revolution Vibe is CE marked and 510(k) pending with the U.S. FDA. Not available for sale in the United States or all regions.

ii Shapiro MD et al. Eur J Radiol. 2008;66(1):37–41. doi:10.1016/j.ejrad.2007.05.006.

iii Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. (2012) 380:2095–128. 10.1016/S0140-6736(12)61728-0. https://pubmed.ncbi.nlm.nih.gov/23245604/

iv IMV. 2023 CT Market Outlook Report (p. 45).

v Walter, M. (2024, November 8). “a huge win”: CMS significantly increases Medicare payments for cardiac CT. Cardiovascular Business. https://cardiovascularbusiness.com/topics/cardiac-imaging/cms-increases-medicare-payments-cardiac-ct-ccta.

vi World Health Organization. Cardiovascular diseases (CVDs). June 11, 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed February 2023

vii Moss AJ et al. The Updated NICE Guidelines: Cardiac CT as the First-Line Test for Coronary Artery Disease. Curr Cardiovasc Imaging Rep (2017) 10: 15.

viii Shapiro MD et al. EurJ Radiol. 2008;66(1):37–41.

ix Pannu HK et al. J Comput Assist Tomogr. 2008 Mar-Apr;32(2):247-51.

x Graaf D et al. American Journal of Cardiology. 2010;105(6):767–772.

xi Techasith T et al. J Cardiovasc Comput Tomogr. 2011;5(4):255–263.

xii Ghoshhajra BB et al. Am J Med. 2012;125(8):764–772.

xiii Hamid S et al. Am J Emerg Med. 2010;28(4):494–498.

xiv Cotarlan V et al. Am J Cardiol. 2013;111(5):661–666.

xv Hoffmann U et al. Am Heart J. 2012;163(3):330-338.

xvi GE HealthCare case study. “Revolution Vibe: A new vision for heart at Radiomed.”

GE HealthCare Media Contact:

Margaret Steinhafel

M +1 608 381 8829

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Technology Medical Devices Cardiology Software Biotechnology Radiology Health Science Artificial Intelligence Other Science

MEDIA:

Logo
Logo
Posted on

Templeton Emerging Markets Income Fund (“TEI” or the “Fund”) Announces Notification of Sources of Distributions

Templeton Emerging Markets Income Fund (“TEI” or the “Fund”) Announces Notification of Sources of Distributions

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–
Templeton Emerging Markets Income Fund [NYSE: TEI]:

Notification of Sources of Distributions

Pursuant to Section 19(a) of the Investment Company Act of 1940

The Fund’s estimated sources of the distribution to be paid on March 31, 2025, and for the fiscal year 2025 year-to-date are as follows:

Estimated Allocations for March Monthly Distribution as of February 28, 2025:

Distribution

Per Share

Net Investment

Income

Net Realized

Short-Term Capital

Gains

Net Realized

Long-Term Capital

Gains

Return of

Capital

$0.0475

$0.0475 (100%)

$0.00 (0%)

$0.00 (0%)

$0.00 (0%)

Cumulative Estimated Allocations fiscal year-to-date as of February 28, 2025, for the fiscal year ending December 31, 2025:

Distribution

Per Share

Net Investment

Income

Net Realized

Short-Term Capital

Gains

Net Realized

Long-Term Capital

Gains

Return of

Capital

$0.0950

$0.0950 (100%)

$0.00 (0%)

$0.00 (0%)

$0.00 (0%)

Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Plan. TEI estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of the TEI distribution to shareholders may be a return of capital. A return of capital may occur, for example, when some or all of the money that a shareholder invested in a Fund is paid back to them. A return of capital distribution does not necessarily reflect TEI’s investment performance and should not be confused with ‘yield’ or ‘income’. The amounts and sources of distributions reported herein are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send a Form 1099-DIV to shareholders for the calendar year that will describe how to report the Fund’s distributions for federal income tax purposes.

Average Annual Total Return (in relation to the change in net asset value (NAV) for the 5-year period ended on 2/28/2025)1

Annualized Distribution Rate (as a percentage of NAV for the current fiscal period through 2/28/2025)2

Cumulative Total Return (in relation to the change in NAV for the fiscal period through 2/28/2025)3

Cumulative Fiscal Year-To-Date Distribution Rate (as a percentage of NAV as of 2/28/2025)4

-1.28%

9.88%

3.80%

1.65%

Fund Performance and Distribution Rate Information:

  1. Average Annual Total Return in relation to NAV represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ended through February 28, 2025. Annual NAV Total Return is the percentage change in the Fund’s NAV over a year, assuming reinvestment of distributions paid.
  2. The Annualized Distribution Rate is the current fiscal period’s distribution rate annualized as a percentage of the Fund’s NAV through February 28, 2025.
  3. Cumulative Total Return is the percentage change in the Fund’s NAV from December 31, 2024 through February 28, 2025, assuming reinvestment of distributions paid.
  4. The Cumulative Fiscal Year-To-Date Distribution Rate is the dollar value of distributions for the fiscal period December 31, 2024 through February 28, 2025, as a percentage of the Fund’s NAV as of February 28, 2025.

The Fund’s Board of Trustees (the “Board”) has authorized a managed distribution plan (the “Plan”) pursuant to which the Fund makes monthly distributions to shareholders at the fixed rate of $0.0475 per share. The Plan is intended to provide shareholders with consistent distributions each month and is intended to narrow the discount between the market price and the net asset value (“NAV”) of the Fund’s common shares, but there can be no assurance that the Plan will be successful in doing so. The Fund is managed with a goal of generating as much of the distribution as possible from net ordinary income and short-term capital gains, that is consistent with the Fund’s investment strategy and risk profile. To the extent that sufficient distributable income is not available on a monthly basis, the Fund will distribute long-term capital gains and/or return of capital in order to maintain its managed distribution rate. A return of capital may occur, for example, when some or all of the money that was invested in the Fund is paid back to shareholders. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with “yield” or “income”. Even though the Fund may realize current year capital gains, such gains may be offset, in whole or in part, by the Fund’s capital loss carryovers from prior years.

The Board may amend the terms of the Plan or terminate the Plan at any time without prior notice to the Fund’s shareholders. The amendment or termination of the Plan could have an adverse effect on the market price of the Fund’s common shares. The Plan will be subject to the periodic review by the Board, including a yearly review of the fixed rate to determine if an adjustment should be made.

For further information on Templeton Emerging Markets Income Fund, please visit our web site at: www.franklintempleton.com

Franklin Resources, Inc. is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. Through its specialist investment managers, the company offers specialization on a global scale, bringing extensive capabilities in fixed income, equity, alternatives and multi-asset solutions. With more than 1,500 investment professionals, and offices in major financial markets around the world, the California-based company has over 75 years of investment experience and $1.58 trillion in assets under management as of February 28, 2025. For more information, please visit franklintempleton.com.

For more information, please contact Franklin Templeton at 1-800-342-5236.

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Posted on

APP INVESTOR ALERT: AppLovin Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

PR Newswire


SAN DIEGO
, March 28, 2025 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AppLovin Corporation (NASDAQ: APP) securities between May 10, 2023 and February 25, 2025, both dates inclusive (the “Class Period”), have until Monday, May 5, 2025 to seek appointment as lead plaintiff of the AppLovin class action lawsuit. Captioned Quiero v. AppLovin Corporation, Inc., No. 25-cv-02294 (N.D. Cal.), the AppLovin class action lawsuit charges AppLovin as well as certain of AppLovin’s top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the AppLovin class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-applovin-corporation-class-action-lawsuit-app.html
 

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: AppLovin engages in building a software-based platform for advertisers to enhance the marketing and monetization of their content.

The AppLovin class action lawsuit alleges that defendants throughout the Class Period created the false impression that AppLovin’s enhanced AXON 2.0 digital ad platform, in addition to its “cutting-edge AI technologies,” would more efficiently match advertisements to mobile games, in addition to expanding into web-based marketing and e-commerce. In truth, AppLovin was exploiting advertising data from Meta Platforms and using manipulative practices that forced unwanted apps on customers via a “backdoor installation scheme” which inaccurately inflated installation numbers, and, in turn, its profit figures, the complaint alleges.

The AppLovin class action lawsuit further alleges that on February 26, 2025, analyst research reports emerged stating that AppLovin was reverse engineering and exploiting advertising data from Meta Platforms. The reports further alleged AppLovin was utilizing manipulative practices to artificially inflate their own ad click-through and app download rates, such as by having ads click on themselves or utilizing design gimmicks to trigger forced shadow downloads, erroneously inflating installation numbers and, in turn, its profit figures, the complaint alleges. On this news, the price of AppLovin shares fell by more than 12%, the AppLovin class action lawsuit alleges.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired AppLovin securities during the Class Period to seek appointment as lead plaintiff in the AppLovin class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the AppLovin class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the AppLovin class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the AppLovin class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices. 

Contact:
            Robbins Geller Rudman & Dowd LLP
            J.C. Sanchez, Jennifer N. Caringal
            655 W. Broadway, Suite 1900, San Diego, CA 92101
            800-449-4900
            [email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/app-investor-alert-applovin-corporation-investors-with-substantial-losses-have-opportunity-to-lead-securities-class-action-lawsuit-302414428.html

SOURCE Robbins Geller Rudman & Dowd LLP

Posted on

SLB Announces First-Quarter 2025 Results Conference Call

SLB Announces First-Quarter 2025 Results Conference Call

HOUSTON–(BUSINESS WIRE)–
SLB (NYSE: SLB) will hold a conference call on April 25, 2025 to discuss the results for the first quarter ending March 31, 2025.

The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time.

To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (404) 975-4839 outside of North America approximately 10 minutes prior to the start of the call and the access code is 114893.

A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/581727555 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until May 2, 2025, and can be accessed by dialing +1 (866) 813-9403 within North America or +1 (929) 458-6194 outside of North America and giving the access code 541892.

About SLB

SLB (NYSE: SLB) is a global technology company that drives energy innovation for a balanced planet. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.

Investors

James R McDonald – SVP of Investor Relations & Industry Affairs

Joy V. Domingo – Director of Investor Relations

Tel: +1 (713) 375-3535

Email: [email protected]

Media

Josh Byerly – SVP of Communications

Moira Duff – Director of External Communications

Tel: +1 (713) 375-3407

Email: [email protected]

slb.com/newsroom

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Technology Other Energy Utilities Other Technology Oil/Gas Alternative Energy Other Natural Resources Energy Mining/Minerals Natural Resources

MEDIA:

Logo
Logo
Posted on

S&P Global Mobility: March 2025 US auto sales potentially ride one last wave

PR Newswire

S&P Global Mobility projects that US auto sales in March will crest over 1.45 million units, as consumers and automakers try to get ahead of tariffs


SOUTHFIELD, Mich.
, March 28, 2025 /PRNewswire/ — With volume for the month projected at 1.45 million units, March 2025 U.S. auto sales are estimated to translate to an estimated sales pace of 16.3 million units (seasonally adjusted annual rate: SAAR), according to S&P Global Mobility. This would bring the SAAR average in the first quarter of the year to a level of 16.0 million units.  While the first quarter of 2025 would reflect progress from a year-ago reading of 15.5 million units, it might be the high mark for a while, as auto tariffs take effect in April.

“Automakers, by way of incentives, and savvy consumers are likely attempting to get ahead of future uncertainty surrounding auto pricing levels by taking advantage of March deals,” said Chris Hopson, principal analyst at S&P Global Mobility. “Downside risks to the auto demand and production environment abound as consumers face potential higher auto prices as a result of expected tariffs to imported vehicles and parts.”

The S&P Global Mobility US auto outlook for 2025 reflects sustained, but more moderate growth levels for light vehicle sales, but consumer pressures and potential auto tariffs create notable downside risks to volume estimates at this time.


U.S. Light Vehicle Sales


Mar 25 (Est)


Feb 25


Mar 24

Total Light Vehicle

Units, NSA

1,454,000

1,219,841

1,432,132

In millions, SAAR

16.3

16.0

15.7

Light Truck

In millions, SAAR

13.3

13.0

12.7

Passenger Car

In millions, SAAR

3.0

3.0

3.0

Source: S&P Global Mobility (Est), U.S. Bureau of Economic Analysis

Continued development of battery-electric vehicle (BEV) sales remains an assumption in the longer term S&P Global Mobility light vehicle sales forecast.  In the immediate term, some month-to-month volatility is anticipated. March BEV share is expected to reach 8.5%, an increase from February reported figures and reflective of the uneasiness as automakers, dealers and consumers continue to digest potential changes to BEV incentives. 

About S&P Global Mobility

At S&P Global Mobility, we provide invaluable insights derived from unmatched automotive data, enabling our customers to anticipate change and make decisions with conviction. Our expertise helps them to optimize their businesses, reach the right consumers, and shape the future of mobility. We open the door to automotive innovation, revealing the buying patterns of today and helping customers plan for the emerging technologies of tomorrow.

S&P Global Mobility is a division of S&P Global (NYSE: SPGI). S&P Global is the world’s foremost provider of credit ratings, benchmarks, analytics and workflow solutions in the global capital, commodity and automotive markets. With every one of our offerings, we help many of the world’s leading organizations navigate the economic landscape so they can plan for tomorrow, today. For more information, visit www.spglobal.com/mobility.

Media Contact:

Michelle Culver

S&P Global Mobility
248.728.7496 or 248.342.6211
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sp-global-mobility-march-2025-us-auto-sales-potentially-ride-one-last-wave-302414514.html

SOURCE S&P Global Mobility